@article{580f214da24d4c85bef7098beb471da7,
title = "The Neuroimmune Pharmacology of SARS-CoV-2",
abstract = "This guest commentary introduces “The Neuroimmune Pharmacology of SARS-CoV-2,” a special theme issue for The Journal of Neuroimmune Pharmacology led by the Society on NeuroImmune Pharmacology. The issue builds on the Society{\textquoteright}s Virtual Workshop on COVID-19 held April 9, 2021. Graphical abstract: Top row from left: Drs. Santosh Kumar, Sowmya Yelamanchili, Pankaj Seth, Jean M. Bidlack; Bottom row from left: Drs. Gurudutt Pendyala, Sanjay Maggirwar, and Sulie L. Chang.[Figure not available: see fulltext.].",
keywords = "COVID-19, Diversity, Early-career investigators, Equity and inclusion, Neuroimmune pharmacology, Oral history, SARS-CoV-2, Therapeutics, Vaccines, Well-being",
author = "Santosh Kumar and Sowmya Yelamanchili and Pankaj Seth and Bidlack, {Jean M.} and Gurudutt Pendyala and Sanjay Maggirwar and Chang, {Sulie L.}",
note = "Funding Information: In collaboration with UNMC, SNIP organized a workshop on COVID-19. Presentation topics ranged from the impact of COVID-19 on health disparity, drug abuse, infectious diseases, and neurological complications, as well as potential therapeutic and vaccine approaches to COVID-19. In advance of this theme issue, the organizing committee of the workshop compiled a brief report (Kumar et al. ) from the four symposia of the workshop: 1) Molecular approaches to COVID-19 pathogenesis and underlying mechanism; 2) Therapeutic and vaccine approaches to COVID-19; 3) Early Career Investigator talks; and 4) Diversity and Inclusion SNIP Committee (DISC) program: Well-being and reflections. The virtual workshop also noted four special talks by NIH officials on COVID-19 and funding opportunities from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA). Funding Information: We thank the National Institute on Mental Health, MH0125670 to Dr. Santosh Kumar, and National Institute on Drug Abuse, DA046258 to Dr. Sulie L. Chang, for supporting the work. We also thank Doug Meigs, from the UNMC Department of Pharmacology and Experimental Neuroscience, for editing assistance with this guest commentary and for his overall coordination assistance on this special theme issue, ?The Neuroimmune Pharmacology of SARS-CoV-2,? in The Journal of Neuroimmune Pharmacology where he is Managing Editor. Funding Information: Originally, from Taiwan, Dr. Chang is Director of the Institute of NeuroImmune Pharmacology and Professor of Biological Sciences and Neuroscience at Seton Hall University. She is also an Adjunct Professor of Graduate Program in Endocrinology & Animal Biosciences, Rutgers Graduate School. Dr. Chang is the current President of SNIP. Dr. Chang has studied the bi-directional interactions between the nervous and immune systems in health and diseases. Her research goal is to address how systemic inflammation-induced modulation of the brain-immune axis leads to behavior disorders related to addiction, cognitive impairment, and other neuronal diseases. Recently, by taking comprehensive integration of in vivo, in vitro and in silico approaches, Dr. Chang{\textquoteright}s research is to study neuroimmunology of health and diseases including spleen atrophy, alcohol abuse and drug addition, pain management, Alzheimer's disease, neuroHIV and neuroCOVID-19. Dr. Chang and her research teams have published over 145 scientific papers and book chapters with significant impact. Dr. Chang{\textquoteright}s research has been continuously funded by NIH since 1989, and she has participated in numerous NIH Study Sections. Acknowledgements Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2021",
month = dec,
doi = "10.1007/s11481-021-10038-z",
language = "English (US)",
volume = "16",
pages = "699--705",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",
number = "4",
}